| Carol H Johnson, OD | |
|
909 Fulton St Se, Minneapolis, MN 55455-4800 | |
| (763) 782-6400 | |
| Not Available |
| Full Name | Carol H Johnson |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 37 Years |
| Location | 909 Fulton St Se, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073591939 | NPI | - | NPPES |
| 339523500 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2134 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Express Care | 3375645179 | 1523 |
News Archive
An article published in Experimental Biology and Medicine reports that supporting cells in the heart, known as fibroblasts, are selectively activated by factors present in heart disease.
Two papers that will appear in the journal Molecular Psychiatry, both receiving advance online release, may help identify gene variants that contribute to the risks of developing obsessive-compulsive disorder (OCD) or Tourette syndrome (TS). Both multi-institutional studies were led by Massachusetts General Hospital (MGH) investigators, and both are the first genome-wide association studies (GWAS) in the largest groups of individuals affected by the conditions.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
› Verified 1 days ago
| Provider Name | University Of Minnesota Physicians |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1477598118 PECOS PAC ID: 9830001189 Enrollment ID: O20031104000532 |
News Archive
An article published in Experimental Biology and Medicine reports that supporting cells in the heart, known as fibroblasts, are selectively activated by factors present in heart disease.
Two papers that will appear in the journal Molecular Psychiatry, both receiving advance online release, may help identify gene variants that contribute to the risks of developing obsessive-compulsive disorder (OCD) or Tourette syndrome (TS). Both multi-institutional studies were led by Massachusetts General Hospital (MGH) investigators, and both are the first genome-wide association studies (GWAS) in the largest groups of individuals affected by the conditions.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
› Verified 1 days ago
| Provider Name | Fairview Express Care |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
An article published in Experimental Biology and Medicine reports that supporting cells in the heart, known as fibroblasts, are selectively activated by factors present in heart disease.
Two papers that will appear in the journal Molecular Psychiatry, both receiving advance online release, may help identify gene variants that contribute to the risks of developing obsessive-compulsive disorder (OCD) or Tourette syndrome (TS). Both multi-institutional studies were led by Massachusetts General Hospital (MGH) investigators, and both are the first genome-wide association studies (GWAS) in the largest groups of individuals affected by the conditions.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
› Verified 1 days ago
| Provider Name | University Of Minnesota Health Clinics And Surgery Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053795187 PECOS PAC ID: 9133423304 Enrollment ID: O20160209000524 |
News Archive
An article published in Experimental Biology and Medicine reports that supporting cells in the heart, known as fibroblasts, are selectively activated by factors present in heart disease.
Two papers that will appear in the journal Molecular Psychiatry, both receiving advance online release, may help identify gene variants that contribute to the risks of developing obsessive-compulsive disorder (OCD) or Tourette syndrome (TS). Both multi-institutional studies were led by Massachusetts General Hospital (MGH) investigators, and both are the first genome-wide association studies (GWAS) in the largest groups of individuals affected by the conditions.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol H Johnson, OD 2925 Chicago Ave, Minneapolis, MN 55407-1321 Ph: (612) 262-1166 | Carol H Johnson, OD 909 Fulton St Se, Minneapolis, MN 55455-4800 Ph: (763) 782-6400 |
News Archive
An article published in Experimental Biology and Medicine reports that supporting cells in the heart, known as fibroblasts, are selectively activated by factors present in heart disease.
Two papers that will appear in the journal Molecular Psychiatry, both receiving advance online release, may help identify gene variants that contribute to the risks of developing obsessive-compulsive disorder (OCD) or Tourette syndrome (TS). Both multi-institutional studies were led by Massachusetts General Hospital (MGH) investigators, and both are the first genome-wide association studies (GWAS) in the largest groups of individuals affected by the conditions.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
› Verified 1 days ago
The Glasses Menagerie Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3142 Hennepin Ave, Minneapolis, MN 55408 Phone: 612-822-7021 | |
Art Of Optiks Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4999 France Ave S, Suite 140, Minneapolis, MN 55410 Phone: 612-440-2020 Fax: 612-440-0202 | |
Dr. Xuanmai Thi Ta, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2718 Nicollet Ave, Suite No. 103, Minneapolis, MN 55408 Phone: 612-871-1518 Fax: 612-871-2585 | |
Dr. Theodore Lester Hansen, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 115 East Lake St, Minneapolis, MN 55408 Phone: 612-827-3857 Fax: 612-827-7204 | |
Kari Maffitt, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3553 Hennepin Ave, Minneapolis, MN 55408 Phone: 612-822-5844 Fax: 612-827-3418 | |
Dr. David Paul Parupsky, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1304 4th St Se, Dinkytown Optical, Minneapolis, MN 55414 Phone: 612-331-7100 Fax: 612-331-7100 | |
Moulay Younes Elidrissi, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 720 W Lake St # 107, Minneapolis, MN 55408 Phone: 612-216-4705 |